



BSW Formulary Updates and Recent Decisions – June 2024

New additions to BSWformulary and Change in Traffic Light Status

- [Sodium acid phosphate with sodium bicarbonate suppository \(Lecicarbon A\)](#) – added to formulary with **amber** TL for use in a very small cohort of pelvic floor patients with dyschezia.
- [Melatonin for sleep disorders in adults with learning disability](#) who also have a co-morbid mental illness (e.g. depression, mania, psychosis, dementia etc.) OR disorder (e.g. autism or autistic spectrum, anxiety disorders, adult ADHD etc.). Added with **amber** TL, specialist initiation and stabilisation for 3/12, and accompanied by [prescribing guidance](#) due to off-label use.
- [Erythropoietin entries](#) – TLS aligned as **red** for all **new** patients. Primary care to review any existing patients and discuss with BSW formulary team via bswicb.formulary@nhs.net to make an appropriate individualised plan for repatriating prescribing back into trusts and ensure prescribing and monitoring is carried out by the most appropriate clinician.
- [Thiamine 50mg/ml injection \(Unlic\)](#) added with **red** tl to cover Pabrinex shortage.
- Two [peptide based ONS](#) added to formulary with **green** tl due to shortages in pancreatic enzyme replacement therapy (PERT). All alternatives in the PERT shortages [guidance](#) are now on BSW formulary.
- [Levobupivacaine 0.125% infusion bag](#) added with **red** tl to help with stock shortages.

Other amendments to BSW formulary

- Wording amended in [imiquimod entry](#) for Superficial Basal Cell Carcinoma to clarify it can be prescribed *on the recommendation* of a consultant dermatologist or GP with special interest in dermatology for this indication.
- [Fludrocortisone 0.05microgram strength](#) (new lower strength) added as non-formulary as local specialists do not consider it cost-effective.
- **Non-formulary** status agreed for [glycopyrronium \(hyperhidrosis indication\)](#) due to poor evidence base and high cost.
- BSW [SCA for somatropin for the treatment of growth hormone deficiency in adults](#) updated to reflect current stock situation and ongoing shortages; no clinical update.
- [Paxlovid entry](#) updated to reflect the change in [NICE](#) eligibility for access for Covid patients.
- Position statement published to note that BSW ICB does **NOT** support routine prescribing of [dessert-style ONS](#). See statement at <https://bswtogether.org.uk/medicines/wp-content/uploads/sites/3/2024/06/BSW-ICB-Position-Statement-on-Prescription-of-Dessert-Style-ONS-FINAL.pdf>



- The SPS website are producing a series of articles on [medicines suitable for adults with swallowing difficulties](#). The articles focus on medicines with relevance to primary care and where there has been a high spend on special-order medicines. We have added the following to relevant entries of BSWformulary and will add further articles as they are published:
- [ACEI suggestions for adults with swallowing difficulties](#)
- [ARB suggestions for adults with swallowing difficulties](#)
- [Anticoagulant suggestions for adults with swallowing difficulties](#)
- [Antiplatelet suggestions for adults with swallowing difficulties](#)
- [Clozapine use in adults with swallowing difficulties](#)
- [Parkinson's disease medicines in swallowing difficulties](#)
- [PPI suggestions for adults with swallowing difficulties](#)
- [SSRI suggestions for adults with swallowing difficulties](#)
- [Statin suggestions for adults with swallowing difficulties](#)

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net